Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Hemostemix Inc (HMTXF)

Hemostemix Inc (HMTXF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementiaCalgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix...

AIFF : 3.12 (-8.50%)
HMTXF : 0.0823 (-19.00%)
HEM.VN : 0.125 (-10.71%)
Hemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture

Calgary, Alberta--(Newsfile Corp. - March 5, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely...

HMTXF : 0.0823 (-19.00%)
HEM.VN : 0.125 (-10.71%)
RETRANSMISSION: Hemostemix Licenses CytoImmune's BioReactor Technologies

Calgary, Alberta--(Newsfile Corp. - February 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that secures...

HMTXF : 0.0823 (-19.00%)
HEM.VN : 0.125 (-10.71%)
Hemostemix Licenses CytoImmune's BioReactor Technologies

Calgary, Alberta--(Newsfile Corp. - February 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that secures...

HMTXF : 0.0823 (-19.00%)
HEM.VN : 0.125 (-10.71%)
Hemostemix Provides Corporate Update

Calgary, Alberta--(Newsfile Corp. - February 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that, at the request of the Canadian Investment...

HMTXF : 0.0823 (-19.00%)
HEM.VN : 0.125 (-10.71%)
Hemostemix PR Inc. Congratulates Luis Munoz Marin International Airport on Achieving CEIV Pharma Certification

San Juan, Puerto Rico--(Newsfile Corp. - February 11, 2025) - Hemostemix PR Inc. proudly congratulates Luis Muñoz Marín International Airport (SJU) on achieving the prestigious CEIV Pharma Certification...

HMTXF : 0.0823 (-19.00%)
HEM.VN : 0.125 (-10.71%)
Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors

Calgary, Alberta--(Newsfile Corp. - February 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to announce that it has engaged ProConsul Capital...

HMTXF : 0.0823 (-19.00%)
HEM.VN : 0.125 (-10.71%)
CytoImmune Subscribes for 1,634,466 Hemostemix Common Shares

Calgary, Alberta--(Newsfile Corp. - February 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce that CytoImmune is subscribing USD...

HMTXF : 0.0823 (-19.00%)
HEM.VN : 0.125 (-10.71%)
Hemostemix Expands to the Dominican Republic

Calgary, Alberta--(Newsfile Corp. - February 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its continued expansion, as the Company...

HMTXF : 0.0823 (-19.00%)
HEM.VN : 0.125 (-10.71%)
Hemostemix Announces First Sales Orders for ACP-01

Calgary, Alberta--(Newsfile Corp. - January 29, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its sales of ACP-01 Treatments...

HMTXF : 0.0823 (-19.00%)
HEM.VN : 0.125 (-10.71%)

Barchart Exclusives

This Super Micro Computer Rival Just Hiked Its Dividend 18%. Is It a Buy Now?
Dell Technologies, a strong rival to Super Micro Computer, has increased its dividend by 18%, showcasing its financial stability and growth potential, and prompting investors to consider whether now is a good time to buy into its promising tech story. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar